577 related articles for article (PubMed ID: 38308006)
1. CRISPR technologies for genome, epigenome and transcriptome editing.
Villiger L; Joung J; Koblan L; Weissman J; Abudayyeh OO; Gootenberg JS
Nat Rev Mol Cell Biol; 2024 Jun; 25(6):464-487. PubMed ID: 38308006
[TBL] [Abstract][Full Text] [Related]
2. Refining CRISPR-based genome and epigenome editing off-targets.
Luo Y
Cell Biol Toxicol; 2019 Aug; 35(4):281-283. PubMed ID: 31227932
[No Abstract] [Full Text] [Related]
3. Rational designs of in vivo CRISPR-Cas delivery systems.
Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 ribonucleoprotein-mediated genome and epigenome editing in mammalian cells.
Bloomer H; Khirallah J; Li Y; Xu Q
Adv Drug Deliv Rev; 2022 Feb; 181():114087. PubMed ID: 34942274
[TBL] [Abstract][Full Text] [Related]
5. A CRISPR-dCas Toolbox for Genetic Engineering and Synthetic Biology.
Xu X; Qi LS
J Mol Biol; 2019 Jan; 431(1):34-47. PubMed ID: 29958882
[TBL] [Abstract][Full Text] [Related]
6. CRISPR Diagnosis and Therapeutics with Single Base Pair Precision.
Lee SH; Park YH; Jin YB; Kim SU; Hur JK
Trends Mol Med; 2020 Mar; 26(3):337-350. PubMed ID: 31791730
[TBL] [Abstract][Full Text] [Related]
7. Epigenome editing by CRISPR/Cas9 in clinical settings: possibilities and challenges.
Pei WD; Zhang Y; Yin TL; Yu Y
Brief Funct Genomics; 2020 May; 19(3):215-228. PubMed ID: 31819946
[TBL] [Abstract][Full Text] [Related]
8. Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery.
Ahmad G; Amiji M
Drug Discov Today; 2018 Mar; 23(3):519-533. PubMed ID: 29326075
[TBL] [Abstract][Full Text] [Related]
9. Genome editing for plant research and crop improvement.
Zhan X; Lu Y; Zhu JK; Botella JR
J Integr Plant Biol; 2021 Jan; 63(1):3-33. PubMed ID: 33369120
[TBL] [Abstract][Full Text] [Related]
10. CRISPR-Based Technologies: Impact of RNA-Targeting Systems.
Terns MP
Mol Cell; 2018 Nov; 72(3):404-412. PubMed ID: 30388409
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Genome Editing and its Potential Enhancement through CRISPR Guide RNA and Cas9 Modifications.
Batzir NA; Tovin A; Hendel A
Pediatr Endocrinol Rev; 2017 Jun; 14(4):353-363. PubMed ID: 28613045
[TBL] [Abstract][Full Text] [Related]
12. Rapid Control of Genome Editing in Human Cells by Chemical-Inducible CRISPR-Cas Systems.
Liu KI; Ramli MNB; Sutrisnoh NB; Tan MH
Methods Mol Biol; 2018; 1772():267-288. PubMed ID: 29754234
[TBL] [Abstract][Full Text] [Related]
13. Hypercompact CRISPR-Cas12j2 (CasĪ¦) enables genome editing, gene activation, and epigenome editing in plants.
Liu S; Sretenovic S; Fan T; Cheng Y; Li G; Qi A; Tang X; Xu Y; Guo W; Zhong Z; He Y; Liang Y; Han Q; Zheng X; Gu X; Qi Y; Zhang Y
Plant Commun; 2022 Nov; 3(6):100453. PubMed ID: 36127876
[No Abstract] [Full Text] [Related]
14. The rapidly advancing Class 2 CRISPR-Cas technologies: A customizable toolbox for molecular manipulations.
Wang J; Zhang C; Feng B
J Cell Mol Med; 2020 Mar; 24(6):3256-3270. PubMed ID: 32037739
[TBL] [Abstract][Full Text] [Related]
15. History of CRISPR-Cas from Encounter with a Mysterious Repeated Sequence to Genome Editing Technology.
Ishino Y; Krupovic M; Forterre P
J Bacteriol; 2018 Apr; 200(7):. PubMed ID: 29358495
[TBL] [Abstract][Full Text] [Related]
16. Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing.
Waryah CB; Moses C; Arooj M; Blancafort P
Methods Mol Biol; 2018; 1767():19-63. PubMed ID: 29524128
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in CRISPR technologies for genome editing.
Song M; Koo T
Arch Pharm Res; 2021 Jun; 44(6):537-552. PubMed ID: 34164771
[TBL] [Abstract][Full Text] [Related]
18. Recent trends in CRISPR-Cas system: genome, epigenome, and transcriptome editing and CRISPR delivery systems.
Bae T; Hur JW; Kim D; Hur JK
Genes Genomics; 2019 Aug; 41(8):871-877. PubMed ID: 31119685
[TBL] [Abstract][Full Text] [Related]
19. Development and application of CRISPR/Cas9 technologies in genomic editing.
Zhang C; Quan R; Wang J
Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy.
Ghaemi A; Bagheri E; Abnous K; Taghdisi SM; Ramezani M; Alibolandi M
Life Sci; 2021 Feb; 267():118969. PubMed ID: 33385410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
